SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77328.19
516.33 (-0.66%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Marksans Pharma Ltd.	Q V PT	8,968 Small Cap	197.90 (-2.58%)	37.37	5.92	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Procter & Gamble Health Ltd.	Q V PT	8,883 Small Cap	5,351.35 (0.70%)	30.06	12.65	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	8,770 Small Cap	557.20 (1.62%)	69.58	3.59	12.22	23.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Shilpa Medicare Ltd.	Q V PT	8,532 Small Cap	436.25 (-1.26%)	57.59	3.47	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Blue Jet Healthcare Ltd.	Q V PT	8,518 Small Cap	491.05 (-0.04%)	29.03	6.58	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Yatharth Hospital & Trauma Care Services Ltd.	Q V+ PT	8,312 Small Cap	862.60 (4.86%)	84.73	4.96	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Jupiter Life Line Hospitals Ltd.	Q V PT	8,192 Small Cap	1,249.40 (-0.78%)	44.24	5.3	18.02	36.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Thyrocare Technologies Ltd.	Q V PT	7,727 Small Cap	485.45 (3.60%)	45.75	11.16	9.62	-1.08	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Sanofi India Ltd.	Q V PT	7,664 Small Cap	3,327.85 (-1.90%)	25.22	10.02	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Aarti Pharmalabs Ltd.	Q V+ PT	6,952 Small Cap	766.80 (-1.26%)	32.77	3.62	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Kovai Medical Center & Hospital Ltd.	Q V+ PT	6,209 Small Cap	5,674.75 (-1.44%)	26.72	5.02	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	FDC Ltd.	Q V PT	6,196 Small Cap	380.55 (1.36%)	26.92	2.48	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Suven Life Sciences Ltd.	Q V+ PT	5,911 Small Cap	224.15 (1.56%)	N/A	3.78	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Supriya Lifescience Ltd.	Q V PT	5,697 Small Cap	707.80 (1.06%)	30.43	4.98	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	5,609 Small Cap	172.85 (3.53%)	N/A	-12.62	-1.35	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Nephrocare Health Services Ltd.	Q V+ PT	5,467 Small Cap	544.85 (-0.23%)	160.05	6.06	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Innova Captab Ltd.	Q V PT	5,010 Small Cap	875.45 (1.44%)	59.01	5.63	20.74	22.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Senores Pharmaceuticals Ltd.	Q V+ PT	4,451 Small Cap	966.55 (3.66%)	311.4	5.99	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Gujarat Themis Biosyn Ltd.	Q V+ PT	4,342 Small Cap	398.45 (-0.01%)	90.87	15.68	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	Artemis Medicare Services Ltd.	Q V PT	4,201 Small Cap	265.35 (-0.28%)	43.38	3.6	10.15	32.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	RPG Life Sciences Ltd.	Q V+ PT	4,067 Small Cap	2,458.95 (-0.89%)	35.63	6.78	11.71	30.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Advanced Enzyme Technologies Ltd.	Q V PT	3,999 Small Cap	357.30 (-0.53%)	33.35	5.88	7.28	11.87	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,900 Small Cap	425.40 (2.26%)	20.85	5.45	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	SMS Pharmaceuticals Ltd.	Q V+ PT	3,886 Small Cap	414.90 (-1.36%)	45.11	5.03	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Orchid Pharma Ltd.	Q V PT	3,571 Small Cap	704.10 (3.33%)	81.41	2.58	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Aarti Drugs Ltd.	Q V+ PT	3,545 Small Cap	388.45 (-2.34%)	17.92	2.41	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Gufic Biosciences Ltd.	Q V PT	3,008 Small Cap	300 (0.93%)	58.97	4.63	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,944 Small Cap	187.75 (-2.54%)	25.42	0.48	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Bliss GVS Pharma Ltd.	Q V PT	2,849 Small Cap	269.35 (-0.94%)	37.9	2.56	8.59	-5.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	2,847 Small Cap	96.98 (-0.92%)	24.79	1.62	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Metropolis Health.	550.30	8.83%
Shree Ganesh Remed.	530.60	8.65%
KMC Speciality Hosp	95.47	6.85%
Guj. Kidney & Super	139.85	6.84%
Nectar Lifesciences	14.39	5.89%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Indoco Remedies	228.20	-9.17%
Windlas Biotech	820.55	-4.24%
Panacea Biotec	388.15	-4.16%
Fermenta Biotech	288.70	-4.07%
Lupin	2,377.90	-3.33%

News about Top Pharma Companies in India

May, 2026

Thyrocare Tech. - Quaterly Results

The Revenue for the quarter ended March 2026 of Rs. 2106.70 millions grew by 21.17 % from Rs. 1738.70 millions.Profit for the quarter ended March 2026 rises by 98.54% to Rs. 435.80 millions from Rs. 219.50 millions.The company reported a good operating profit of 763.50 millions compared to 601.80 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	2106.70	1738.70	21.17	7742.70	6331.00	22.30	7742.70	6331.00	22.30
Other Income	37.20	45.40	-18.06	133.90	133.40	0.37	133.90	133.40	0.37
PBIDT	763.50	601.80	26.87	2697.20	2003.60	34.62	2697.20	2003.60	34.62
Interest	14.30	6.00	138.33	21.80	26.30	-17.11	21.80	26.30	-17.11
PBDT	749.20	595.80	25.75	2615.70	1977.30	32.29	2615.70	1977.30	32.29
Depreciation	129.40	117.80	9.85	511.70	465.20	10.00	511.70	465.20	10.00
PBT	619.80	478.00	29.67	2104.00	1512.10	39.14	2104.00	1512.10	39.14
TAX	184.00	258.50	-28.82	615.90	554.30	11.11	615.90	554.30	11.11
Deferred Tax	23.50	114.20	-79.42	43.00	76.60	-43.86	43.00	76.60	-43.86
PAT	435.80	219.50	98.54	1488.10	957.80	55.37	1488.10	957.80	55.37
Equity	1591.70	529.90	200.38	1591.70	529.90	200.38	1591.70	529.90	200.38
PBIDTM(%)	36.24	34.61	4.71	34.84	31.65	10.07	34.84	31.65	10.07

May, 2026

Innova Captab - Quaterly Results

The Sales for the quarter ended March 2026 of Rs. 3582.77 millions rose by 47.73% from Rs. 2425.22 millions.Modest increase of 23.57% in the Net Profit was reported from. 171.25 millions to Rs. 211.62 millions.Operating profit surged to 413.19 millions from the corresponding previous quarter of 325.36 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	3582.77	2425.22	47.73	12988.14	9580.61	35.57	12988.14	9580.61	35.57
Other Income	26.80	43.56	-38.48	132.43	167.75	-21.06	132.43	167.75	-21.06
PBIDT	413.19	325.36	26.99	1646.10	1390.74	18.36	1646.10	1390.74	18.36
Interest	39.81	18.69	113.00	154.21	21.68	611.30	154.21	21.68	611.30
PBDT	373.38	306.67	21.75	1491.89	1369.06	8.97	1491.89	1369.06	8.97
Depreciation	94.03	78.12	20.37	373.67	170.15	119.61	373.67	170.15	119.61
PBT	279.35	228.55	22.23	1118.22	1198.91	-6.73	1118.22	1198.91	-6.73
TAX	67.73	57.30	18.20	281.30	304.21	-7.53	281.30	304.21	-7.53
Deferred Tax	58.38	29.89	95.32	103.65	84.21	23.09	103.65	84.21	23.09
PAT	211.62	171.25	23.57	836.92	894.70	-6.46	836.92	894.70	-6.46
Equity	572.25	572.25	0.00	572.25	572.25	0.00	572.25	572.25	0.00
PBIDTM(%)	11.53	13.42	-14.04	12.67	14.52	-12.69	12.67	14.52	-12.69

May, 2026

SMS Pharmaceuticals informs about newspaper publication

SMS Pharmaceuticals has enclosed copies of the newspaper advertisements published today in the the Financial Express (English), and in Nava Telangana (Telugu), informing about the Investor Education and Protection Fund Authority’s (IEPFA) ‘Second 100-Days CampaignSaksham Niveshak’. This information is also being uploaded on the Company’s website at www.smspharma.com

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Sanofi India informs about press release

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India has informed that it enclosed press release titled 'Sanofi India Limited appoints Mr. Rahul Bhatnagar as the Chairman of its Board of Directors’.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Sun Pharma Advanced Research Company informs about press release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharma Advanced Research Company has informed that it enclosed the Press Release titled ‘SPARC Announces Sale of Priority Review Voucher for US $ 195 million (One Hundred and Ninety-Five Million Dollars)’, which the company shall be releasing after sending this letter. The disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR’) read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 for the Sale of Priority Review Voucher is provided in Annexure A.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

SPARC surges after inking pact to sell Priority Review Voucher for $195 million

PRV was granted by the U.S. Food and Drug Administration for the approval of Sezaby indicated for the treatment of neonatal seizures

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,43,229 Crore
2	Divis Laboratories Ltd.	1,78,100 Crore
3	Torrent Pharmaceuticals Ltd.	1,48,251 Crore
4	Apollo Hospitals Enterprise Ltd.	1,16,392 Crore
5	Cipla Ltd.	1,08,865 Crore
6	Lupin Ltd.	1,08,721 Crore
7	Dr. Reddys Laboratories Ltd.	1,07,942 Crore
8	Mankind Pharma Ltd.	1,00,200 Crore
9	Max Healthcare Institute Ltd.	98,526 Crore
10	Zydus Lifesciences Ltd.	94,475 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,661	56,654	37.17	12.91	26.02	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	65.25	16.32	36.87	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	24.45
Lupin Ltd. (M)	Somewhat Good	2,378	1,08,721	20.39	4.84	11.79	20.83
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	110
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,364	66,722	67.00
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	40.02
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	37.62
Gland Pharma Ltd. (S)	Very Good	1,904	31,377	34.73
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	17.81
Mankind Pharma Ltd. (M)	Very Good	2,427	1,00,200	58.82	6.28	35.25	14.65
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	74.68	12.52	37.46	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	30.57
Cipla Ltd. (L)	Very Good	1,348	1,08,865	23.95	3.24	14.44	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,847	4,43,229	40.61	5.46	22.21	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Thyrocare Tech. - Quaterly Results

Innova Captab - Quaterly Results

SMS Pharmaceuticals informs about newspaper publication

Sanofi India informs about press release

Sun Pharma Advanced Research Company informs about press release

SPARC surges after inking pact to sell Priority Review Voucher for $195 million

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.